Schrödinger (NASDAQ:SDGR) Third Quarter 2022 Results
Key financial results
- Revenue: US$37.0 million (24% more than in 3Q 2021).
- Net Loss: $39.9 million (loss up 14% from 3Q 2021).
- US$0.56 loss per share (further deteriorated from US$0.49 loss in 3Q 2021).
All figures in the chart above are for the last 12 months (TTM) period
Schrödinger Income Insights
Looking ahead, revenue is forecast to grow at an average 33% per annum over the next 3 years, compared to a 14% growth forecast for the US Healthcare Services sector.
Performance of the US Healthcare Services Industry.
The company’s shares are down 14% from a week ago.
Just as investors must consider income, it is also important to consider the strength of a company’s balance sheet. We have a graphical representation of Schrödinger’s balance sheet and an in-depth analysis of the company’s financial position.
Valuation is complex, but we help make it simple.
Find out if Schrodinger may be over- or undervalued by reviewing our comprehensive analysis, including: fair value estimates, risks and cautions, dividends, insider trading and financial health.
View the free analysis
Do you have any feedback on this article? Concerned about the content? Contact us directly with us. You can also email the editorial team at (at) Simplywallst.com.
This article from Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended as financial advice. It does not constitute a recommendation to buy or sell shares and does not take into account your objectives or your financial situation. We strive to provide you with long-term focused analysis powered by fundamental data. Please note that our analysis may not take into account the latest price-sensitive company announcements or quality material. Simply Wall St has no position in said stocks.